CTGov Compliance My Organizations

Compliance Rate

Compliance Rate 0%

Compliant submissions 0

Incompliant submissions 0

Total trials 0

My Organizations' Clinical Trials

Showing 150 of 275 entries

View as:

Assessment of Subject Use of the Rebiject II Injection Device According to Nurse Examination of Subject Accuracy in 10 Steps as a Dummy Demonstration

Phase: N/A Priority: Normal

NCT ID: NCT01195857 Org: User:

Start: 01/31/09 End: 09/30/09 Due: 09/30/10

EMD 525797 in Colorectal and Ovarian Cancer Patients With Liver Metastases

Phase: N/A Priority: Normal

NCT ID: NCT00848510 Org: User:

Start: 02/28/09 End: 11/30/13 Due: 11/30/14

An Observational Study to Document the Effectiveness and Compatibility of Rebif 44 or 22 µg in the Therapy of the Chronic Multiple Sclerosis

Phase: N/A Priority: Normal

NCT ID: NCT01142557 Org: User:

Start: 06/30/04 End: 11/30/05 Due: 11/30/06

To Assess the Level of Adherence of Subjects Receiving SAIZEN® Via Easypod™ in Hungary

Phase: N/A Priority: Normal

NCT ID: NCT01402999 Org: User:

Start: 05/31/12 End: 12/31/15 Due: 12/31/16

Cilengitide Imaging Trial in Glioblastoma

Phase: N/A Priority: Normal

NCT ID: NCT01558687 Org: User:

Start: 08/31/12 End: 02/28/13 Due: 02/28/14

A Post-Marketing Surveillance Study On Erbitux® (Cetuximab) In Patients With Metastatic Colorectal Cancer Refractory To Irinotecan Containing Treatment

Phase: N/A Priority: Normal

NCT ID: NCT01134640 Org: User:

Start: 01/31/08 End: 11/30/10 Due: 11/30/11

Phase I/Ib Multiple Ascending Dose Study in China

Phase: N/A Priority: Normal

NCT ID: NCT03523390 Org: User:

Start: 04/24/18 End: 02/08/21 Due: 02/08/22

Phase 3 Trial to Evaluate the Efficacy and Safety of COL-1620 Vaginal Progesterone Gel

Phase: N/A Priority: Normal

NCT ID: NCT01863680 Org: User:

Start: 07/31/13 End: 10/31/14 Due: 10/31/15

A Japanese Trial of TH-302 in Subjects With Locally Advanced Unresectable or Metastatic Soft Tissue Sarcoma

Phase: N/A Priority: Normal

NCT ID: NCT02255110 Org: User:

Start: 12/10/14 End: 01/12/16 Due: 01/12/17

Relative Bioavailability Trial of L-Praziquantel in Healthy Volunteers

Phase: N/A Priority: Normal

NCT ID: NCT02271984 Org: User:

Start: 10/31/14 End: 12/31/14 Due: 12/31/15

TiLE (Time Lapse Eeva) Clinical Trial

Phase: N/A Priority: Normal

NCT ID: NCT02417441 Org: User:

Start: 06/29/15 End: 02/09/17 Due: 02/09/18

Cancer Vaccine Study for Stage III, Unresectable, Non-small Cell Lung Cancer (NSCLC) in the Asian Population

Phase: N/A Priority: Normal

NCT ID: NCT01015443 Org: User:

Start: 12/31/09 End: 06/30/15 Due: 06/30/16

A Multicentre, Open Label, Phase 1 Trial in Japan of the Mitogen Activated Protein Extracellular Signal Regulated Kinase (MEK) Inhibitor Pimasertib Given Orally to Subjects With Solid Tumors as Monotherapy

Phase: N/A Priority: Normal

NCT ID: NCT01668017 Org: User:

Start: 09/30/12 End: 05/31/15 Due: 05/31/16

Drug-Drug Interaction of Cladribine and Pantoprazole in Multiple Sclerosis Subjects

Phase: N/A Priority: Normal

NCT ID: NCT00938366 Org: User:

Start: 01/31/08 End: 01/31/09 Due: 01/31/10

Phase III Trial to Assess Efficacy and Safety of Cetuximab for the Treatment of Chinese Participants With Head and Neck Cancer

Phase: N/A Priority: Normal

NCT ID: NCT02383966 Org: User:

Start: 07/31/15 End: 12/20/21 Due: 12/20/22

EMD 525797 in Combination With Cetuximab and Irinotecan in K-ras Wild Type Metastatic Colorectal Cancer

Phase: N/A Priority: Normal

NCT ID: NCT01008475 Org: User:

Start: 10/31/09 End: 04/30/15 Due: 04/30/16

Anti-cancer MUC1-specific Immunotherapy for Unresectable Stage III Non-small Cell Lung Cancer

Phase: N/A Priority: Normal

NCT ID: NCT01731587 Org: User:

Start: 01/31/01 End: - Due: -

Research on Nicorandil Treatment of Patients Diagnosed as CHD (Coronary Heart Disease) With Stable Angina

Phase: N/A Priority: Normal

NCT ID: NCT01396395 Org: User:

Start: 09/30/11 End: 05/31/14 Due: 05/31/15

Glucophage® Extended Release (XR) 750 Milligram (mg) Indonesia Bioequivalence (BE) Study

Phase: N/A Priority: Normal

NCT ID: NCT03583385 Org: User:

Start: 08/16/18 End: 10/05/18 Due: 10/05/19

Matuzumab Treatment With Epirubicin, Cisplatin and Capecitabine (ECX) in Esophago-Gastric Cancer

Phase: N/A Priority: Normal

NCT ID: NCT00215644 Org: User:

Start: 08/31/05 End: 08/31/08 Due: 08/31/09

Colposeptine for the Treatment of Bacterial Vaginosis

Phase: N/A Priority: Normal

NCT ID: NCT01153958 Org: User:

Start: 07/31/10 End: 11/30/10 Due: 11/30/11

Treatment Adherence When Using RebiSmart™ in Relapsing Multiple Sclerosis Subjects

Phase: N/A Priority: Normal

NCT ID: NCT01128075 Org: User:

Start: 08/31/09 End: 04/30/14 Due: 04/30/15

SJ-0021 (Gonalef®) Versus Purified Pituitary Gonadotropin (Fertinorm-P®) for Ovulation Induction in Japanese Infertile Women

Phase: N/A Priority: Normal

NCT ID: NCT01185782 Org: User:

Start: 02/28/07 End: 12/31/07 Due: 12/31/08

ChangE From Any Systemic psoriasiS therapY to Raptiva

Phase: N/A Priority: Normal

NCT ID: NCT00697593 Org: User:

Start: 01/31/08 End: 04/30/09 Due: 04/30/10

EMD 521873 Plus Radiotherapy in Non Small Cell Lung Cancer (NSCLC)

Phase: N/A Priority: Normal

NCT ID: NCT00879866 Org: User:

Start: 04/30/09 End: 09/30/12 Due: 09/30/13

Title	NCT ID	Organization	User	Status	Start Date	End Date	Reporting Due Date	Last Checked	User Role	Org Created
Assessment of Subject Use of the Rebiject II Injection Device According to Nurse Examination of Subject Accuracy in 10 Steps as a Dummy Demonstration	NCT01195857	Merck KGaA, Darmstadt, Germany	user2@example.com	None	2009-01-31	2009-09-30	2010-09-30	-	-	2025-07-14
EMD 525797 in Colorectal and Ovarian Cancer Patients With Liver Metastases	NCT00848510	Merck KGaA, Darmstadt, Germany	user2@example.com	None	2009-02-28	2013-11-30	2014-11-30	-	-	2025-07-14
An Observational Study to Document the Effectiveness and Compatibility of Rebif 44 or 22 µg in the Therapy of the Chronic Multiple Sclerosis	NCT01142557	Merck KGaA, Darmstadt, Germany	user2@example.com	None	2004-06-30	2005-11-30	2006-11-30	-	-	2025-07-14
To Assess the Level of Adherence of Subjects Receiving SAIZEN® Via Easypod™ in Hungary	NCT01402999	Merck KGaA, Darmstadt, Germany	user2@example.com	None	2012-05-31	2015-12-31	2016-12-31	-	-	2025-07-14
Cilengitide Imaging Trial in Glioblastoma	NCT01558687	Merck KGaA, Darmstadt, Germany	user2@example.com	None	2012-08-31	2013-02-28	2014-02-28	-	-	2025-07-14
A Post-Marketing Surveillance Study On Erbitux® (Cetuximab) In Patients With Metastatic Colorectal Cancer Refractory To Irinotecan Containing Treatment	NCT01134640	Merck KGaA, Darmstadt, Germany	user2@example.com	None	2008-01-31	2010-11-30	2011-11-30	-	-	2025-07-14
Phase I/Ib Multiple Ascending Dose Study in China	NCT03523390	Merck KGaA, Darmstadt, Germany	user2@example.com	None	2018-04-24	2021-02-08	2022-02-08	-	-	2025-07-14
Phase 3 Trial to Evaluate the Efficacy and Safety of COL-1620 Vaginal Progesterone Gel	NCT01863680	Merck KGaA, Darmstadt, Germany	user2@example.com	None	2013-07-31	2014-10-31	2015-10-31	-	-	2025-07-14
A Japanese Trial of TH-302 in Subjects With Locally Advanced Unresectable or Metastatic Soft Tissue Sarcoma	NCT02255110	Merck KGaA, Darmstadt, Germany	user2@example.com	None	2014-12-10	2016-01-12	2017-01-12	-	-	2025-07-14
Relative Bioavailability Trial of L-Praziquantel in Healthy Volunteers	NCT02271984	Merck KGaA, Darmstadt, Germany	user2@example.com	None	2014-10-31	2014-12-31	2015-12-31	-	-	2025-07-14
TiLE (Time Lapse Eeva) Clinical Trial	NCT02417441	Merck KGaA, Darmstadt, Germany	user2@example.com	None	2015-06-29	2017-02-09	2018-02-09	-	-	2025-07-14
Cancer Vaccine Study for Stage III, Unresectable, Non-small Cell Lung Cancer (NSCLC) in the Asian Population	NCT01015443	Merck KGaA, Darmstadt, Germany	user2@example.com	None	2009-12-31	2015-06-30	2016-06-30	-	-	2025-07-14
A Multicentre, Open Label, Phase 1 Trial in Japan of the Mitogen Activated Protein Extracellular Signal Regulated Kinase (MEK) Inhibitor Pimasertib Given Orally to Subjects With Solid Tumors as Monotherapy	NCT01668017	Merck KGaA, Darmstadt, Germany	user2@example.com	None	2012-09-30	2015-05-31	2016-05-31	-	-	2025-07-14
Drug-Drug Interaction of Cladribine and Pantoprazole in Multiple Sclerosis Subjects	NCT00938366	Merck KGaA, Darmstadt, Germany	user2@example.com	None	2008-01-31	2009-01-31	2010-01-31	-	-	2025-07-14
Phase III Trial to Assess Efficacy and Safety of Cetuximab for the Treatment of Chinese Participants With Head and Neck Cancer	NCT02383966	Merck KGaA, Darmstadt, Germany	user2@example.com	None	2015-07-31	2021-12-20	2022-12-20	-	-	2025-07-14
EMD 525797 in Combination With Cetuximab and Irinotecan in K-ras Wild Type Metastatic Colorectal Cancer	NCT01008475	Merck KGaA, Darmstadt, Germany	user2@example.com	None	2009-10-31	2015-04-30	2016-04-30	-	-	2025-07-14
Anti-cancer MUC1-specific Immunotherapy for Unresectable Stage III Non-small Cell Lung Cancer	NCT01731587	Merck KGaA, Darmstadt, Germany	user2@example.com	None	2001-01-31	-	-	-	-	2025-07-14
Research on Nicorandil Treatment of Patients Diagnosed as CHD (Coronary Heart Disease) With Stable Angina	NCT01396395	Merck KGaA, Darmstadt, Germany	user2@example.com	None	2011-09-30	2014-05-31	2015-05-31	-	-	2025-07-14
Glucophage® Extended Release (XR) 750 Milligram (mg) Indonesia Bioequivalence (BE) Study	NCT03583385	Merck KGaA, Darmstadt, Germany	user2@example.com	None	2018-08-16	2018-10-05	2019-10-05	-	-	2025-07-14
Matuzumab Treatment With Epirubicin, Cisplatin and Capecitabine (ECX) in Esophago-Gastric Cancer	NCT00215644	Merck KGaA, Darmstadt, Germany	user2@example.com	None	2005-08-31	2008-08-31	2009-08-31	-	-	2025-07-14
Colposeptine for the Treatment of Bacterial Vaginosis	NCT01153958	Merck KGaA, Darmstadt, Germany	user2@example.com	None	2010-07-31	2010-11-30	2011-11-30	-	-	2025-07-14
Treatment Adherence When Using RebiSmart™ in Relapsing Multiple Sclerosis Subjects	NCT01128075	Merck KGaA, Darmstadt, Germany	user2@example.com	None	2009-08-31	2014-04-30	2015-04-30	-	-	2025-07-14
SJ-0021 (Gonalef®) Versus Purified Pituitary Gonadotropin (Fertinorm-P®) for Ovulation Induction in Japanese Infertile Women	NCT01185782	Merck KGaA, Darmstadt, Germany	user2@example.com	None	2007-02-28	2007-12-31	2008-12-31	-	-	2025-07-14
ChangE From Any Systemic psoriasiS therapY to Raptiva	NCT00697593	Merck KGaA, Darmstadt, Germany	user2@example.com	None	2008-01-31	2009-04-30	2010-04-30	-	-	2025-07-14
EMD 521873 Plus Radiotherapy in Non Small Cell Lung Cancer (NSCLC)	NCT00879866	Merck KGaA, Darmstadt, Germany	user2@example.com	None	2009-04-30	2012-09-30	2013-09-30	-	-	2025-07-14

Compliance Rate

My Organizations' Clinical Trials

Appearance